background
immunofluoresc
viru
cultur
main
method
use
diagnos
acut
respiratori
viru
infect
diagnos
infect
use
nucleic
acid
amplif
present
technic
challeng
one
facilit
differ
optim
anneal
temperatur
need
viru
overcom
problem
develop
diagnost
molecular
strip
combin
gener
nest
touchdown
protocol
inhous
primer
mastermix
could
recognis
common
respiratori
virus
result
month
period
total
specimen
test
immunofluoresc
molecular
strip
specimen
came
male
median
age
femal
median
age
qualiti
assur
scheme
specimen
virus
recov
number
specimen
type
includ
bronchoalveolar
lavag
nasopharyng
secret
sputa
postmortem
lung
tissu
combin
throat
nasal
swab
viral
detect
poor
sputa
respiratori
swab
total
virus
detect
studi
patient
qualiti
control
specimen
immunofluoresc
use
molecular
strip
strip
consist
outperform
immunofluoresc
loss
diagnost
specif
touchdown
protocol
predispens
primer
mastermix
suitabl
replac
viru
cultur
diagnosi
respiratori
virus
neg
immunofluoresc
result
immunofluoresc
avail
averag
hour
molecular
strip
result
avail
within
hour
consider
faster
viral
cultur
combin
strip
touchdown
protocol
prove
conveni
reliabl
method
test
multipl
virus
routin
set
acut
respiratori
tract
infect
major
caus
morbid
mortal
lower
respiratori
tract
infect
global
number
one
infecti
caus
disabl
adjust
lifeyear
commonest
respiratori
virus
caus
acut
upper
lower
respiratori
tract
infect
routin
test
viru
diagnost
laboratori
influenza
viru
fla
influenza
b
viru
flb
respiratori
syncyti
viru
rsv
parainfluenza
viru
type
parainfluenza
viru
type
parainfluenza
viru
type
adenoviru
adv
addit
human
rhinovirus
hrv
coronaviru
also
link
acut
respiratori
infect
less
commonli
includ
laboratori
report
human
metapneumoviru
hmpv
yet
part
unit
kingdom
viru
laboratori
test
repertoir
person
feedback
unit
kingdom
clinic
virolog
network
part
servic
develop
necessari
provid
altern
viru
cultur
test
immunofluoresc
neg
respiratori
specimen
histor
inde
current
immunofluoresc
viru
cultur
main
method
use
diagnos
acut
respiratori
viru
infect
cultur
accept
sensit
immunofluoresc
slower
therefor
less
use
direct
patient
manag
decis
use
standard
cultur
techniqu
cultur
respiratori
virus
median
report
time
cultur
posit
cultur
neg
specimen
day
base
specimen
day
base
specimen
respect
viru
identif
techniqu
requir
use
monoclon
antibodi
stain
cell
monolay
addit
observ
viral
cytopath
effect
therefor
wish
develop
test
capabl
report
immunofluoresc
neg
specimen
within
hour
period
increasingli
howev
sensit
nucleic
acid
amplif
techniqu
diagnosi
becom
recognis
howev
widespread
concern
contamin
issu
perceiv
cost
slow
widespread
adopt
ad
problem
acut
respiratori
tract
infect
rel
larg
number
virus
need
account
problem
present
specif
technic
challeng
one
challeng
differ
optim
anneal
temperatur
primer
set
prospect
viru
target
abi
prism
realtim
facil
appli
biosystem
address
use
bundl
softwar
design
primerprob
combin
use
common
amplif
protocol
howev
approach
compromis
inabl
softwar
allow
target
heterogen
addit
allow
user
adopt
clinic
valid
primer
set
literatur
address
problem
adopt
altern
approach
develop
gener
touchdown
amplif
protocol
touchdown
protocol
involv
predesign
step
reduct
anneal
temperatur
use
primertotempl
bind
introduc
competit
advantag
specif
basepair
prime
nonspecif
prime
detail
knowledg
optimum
anneal
temperatur
therefor
requir
studi
protocol
empir
construct
prove
robust
appli
larg
rang
respiratori
viral
bacteri
target
without
compromis
individu
test
sensit
design
use
inhous
primer
mastermix
recognis
common
respiratori
virus
decid
layout
molecular
strip
describ
method
undertook
wide
rang
preliminari
valid
step
primer
set
complex
strip
make
imposs
fulli
evalu
use
classic
approach
appli
individu
gold
standard
viru
type
classic
approach
work
well
singl
target
investig
howev
although
strip
put
design
identifi
virus
actual
number
individu
type
target
one
hundr
sixti
inclus
gener
primer
set
hrv
adv
respect
classic
approach
compound
virus
grown
grown
easili
b
commerci
sera
avail
c
specimen
panel
avail
therefor
adopt
phase
valid
culmin
present
studi
sensit
ascrib
undertak
copi
number
determin
clone
target
rang
form
copi
per
ml
human
rhinoviru
type
copiesml
rsva
specif
ascrib
reproduc
ie
specimen
repeatedli
posit
follow
standard
clinic
report
algorithm
regard
true
posit
similar
approach
recent
describ
hmpv
addit
amplicon
sequenc
use
initi
specif
check
primer
set
test
clinic
respiratori
specimen
aris
number
ethic
approv
studi
includ
respiratori
specimen
patient
chronic
obstruct
pulmonari
diseas
b
acut
asthma
c
assist
ventil
intens
care
also
test
respiratori
specimen
collect
part
influenza
spotter
program
well
laboratori
specimen
known
viru
reactiv
test
feasibl
routin
use
need
clinic
valid
perform
routin
set
specimen
test
parallel
standard
immunofluoresc
protocol
diagnosi
acut
viru
respiratori
infect
although
routin
immunofluores
panel
lack
capac
detect
rhinovirus
human
metapneumoviru
includ
strip
clinic
reason
period
studi
find
implic
report
total
virus
detect
specimen
total
patient
nation
extern
qualiti
assur
scheme
neqa
control
immunofluoresc
detect
parainfluenza
viru
type
viru
one
neqa
specimen
virus
detect
specimen
type
process
molecular
strip
detect
viru
bronchoalveolar
lavag
nasopharyng
secret
sputa
combin
throat
nasal
swab
immunofluoresc
detect
viru
bronchoalveolar
lavag
nasopharyng
secret
sputa
combin
throat
nasal
swab
median
age
male
femal
patient
viru
detect
rang
week
year
week
year
respect
sixteen
virus
detect
specimen
confirm
respiratori
viru
patient
investig
gener
practic
seventynin
virus
detect
specimen
confirm
respiratori
viru
patient
investig
hospit
virus
detect
specimen
commun
pcr
detect
contrast
singl
identif
influenza
immunofluoresc
pcr
identifi
one
virus
specimen
patient
neqa
posit
specimen
detect
total
virus
shown
tabl
virus
detect
influenza
viru
influenza
viru
influenza
b
viru
human
rhinoviru
adenoviru
parainfluenza
viru
type
parainfluenza
viru
type
respiratori
syncyti
viru
type
respiratori
syncyti
viru
type
b
parainfluenza
viru
type
coronaviru
human
metapneumoviru
detect
dual
infect
detect
patient
dual
infect
influenza
adenoviru
influenza
viru
rhinoviru
influenza
adenoviru
adenoviru
rhinoviru
respiratori
syncyti
viru
type
b
rhinoviru
nine
patient
one
specimen
taken
day
viru
detect
least
one
specimen
pcr
patient
viru
detect
specimen
virus
identifi
rhinoviru
adenoviru
parainfluenza
type
latter
also
immunofluoresc
posit
case
rhinoviru
detect
one
specimen
part
separ
rhinoviru
valid
protocol
one
specimen
subject
retest
coupl
limit
sequenc
noncod
region
amplicon
confirm
presenc
rhinoviru
sequenc
addit
prematur
twin
boy
admit
intens
care
day
sever
bronchiol
evid
acut
rhinoviru
infect
pcr
limit
sequenc
noncod
region
virus
part
rhinoviru
valid
protocol
confirm
presenc
ident
sequenc
rhinoviru
specimen
although
touchdown
pcr
use
success
help
overcom
uncertainti
associ
thermal
amplif
microbi
nucleic
acid
target
use
studi
extend
role
brought
closer
goal
undertak
molecular
diagnost
routin
set
previous
main
impact
seen
multiplex
degener
primer
need
problem
choos
correct
anneal
temperatur
difficult
studi
larg
number
target
main
problem
encount
use
empir
approach
seri
amplif
step
link
step
reduct
anneal
temperatur
construct
prove
extrem
resili
use
wide
rang
primer
set
includ
appar
anomali
put
adenoviru
initi
revers
transcript
step
stream
line
target
singl
strip
previous
report
approach
test
group
f
adenoviru
alongsid
noroviru
astroviru
rotaviru
touchdown
surprisingli
outperform
individu
amplif
protocol
optimis
anneal
temperatur
thu
prove
suitabl
use
divers
rang
respiratori
virus
address
studi
multipl
viral
target
sought
clinic
practic
believ
feasibl
correl
perform
new
assay
headtohead
comparison
alreadi
routin
use
unfortun
mani
clinic
laboratori
elus
test
wider
rang
virus
case
inocul
cell
line
theoret
abil
grow
respect
virus
annual
report
clinic
laboratori
one
commonest
human
respiratori
virus
human
rhinoviru
exampl
use
touchdown
protocol
report
approxim
hrv
infect
per
annum
report
adenoviru
standard
method
pauciti
hmpv
report
underlin
assert
abil
simultan
valid
perform
multipl
molecular
primer
set
routin
clinic
set
major
accomplish
current
methodolog
approach
result
demonstr
rang
primer
medic
literatur
inhous
develop
could
amplifi
singl
gener
touchdown
protocol
therefor
confirm
feasibl
directli
incorpor
primer
set
standard
oper
procedur
without
necess
individu
optimis
cycl
paramet
studi
result
facilit
primer
select
formal
critic
evalu
describ
exampl
enhanc
flexibl
recent
replac
primer
set
influenza
respect
copi
number
sensit
copi
per
ml
gener
matrix
set
copi
number
sensit
copi
per
ml
use
strip
contain
predispens
mastermix
facilit
use
routin
set
laboratori
personnel
thaw
strip
add
specimen
extract
make
aliquot
routin
use
larg
rang
multireact
mastermix
repeatedli
subject
freezethaw
cycl
requir
daili
basi
provid
mix
handl
ice
remain
extrem
stabl
mani
month
requir
howev
strip
design
singl
use
thu
goe
singl
freezethaw
cycl
mix
stabil
problem
singl
posit
control
use
confirm
touchdown
amplif
cycl
run
success
techniqu
use
nest
amplif
follow
run
agaros
gel
electrophoresi
rel
cumbersom
import
evalu
complet
protocol
inclus
report
gener
would
perform
introduc
routin
linemanag
diagnost
set
month
studi
techniqu
fit
well
demand
routin
servic
central
use
predispens
qualiti
check
primer
mastermix
allow
molecular
strip
adapt
use
routin
laboratori
studi
confirm
broad
base
molecular
approach
feasibl
altern
viru
cultur
support
immunofluoresc
diagnosi
respiratori
virus
overal
superior
perform
strip
miss
neqa
specimen
immunofluoresc
underlin
need
sensit
backup
neg
specimen
nest
protocol
must
regard
pragmat
interim
solut
perfect
singl
round
system
avail
format
strip
reduc
concern
attach
nest
format
ie
fals
posit
result
experi
littl
evid
support
contamin
aris
environment
sourc
two
major
point
contamin
nest
system
crosscontamin
manual
extract
b
contamin
second
round
adjac
well
product
first
round
posit
amplif
use
qiagen
biorobot
extract
specimen
reduc
former
natur
strip
prevent
latter
sinc
well
separ
mix
tabl
nest
nonnest
assay
critic
requir
reliabl
result
use
well
train
appropri
skill
knowledg
staff
oper
manag
environ
servic
test
perform
must
stand
extern
intern
qualiti
assur
regard
welcom
new
respiratori
qualiti
control
panel
soon
made
avail
qualiti
control
molecular
diagnost
qcmd
glasgow
result
obtain
encourag
although
strip
construct
detect
wider
rang
virus
immunofluoresc
period
valid
almost
doubl
versu
number
virus
could
detect
immunofluoresc
includ
posit
neqa
specimen
miss
immunofluoresc
group
virus
detect
adenoviru
show
dramat
increas
observ
also
previous
made
separ
studi
continu
see
routin
respiratori
specimen
number
respiratori
studi
similar
hrv
virus
believ
common
infect
underdiagnos
standard
techniqu
immunofluoresc
cultur
second
commonest
viru
hrv
observ
mix
infect
selfevid
addit
infect
level
detect
threshold
standard
method
clinic
signific
detect
lower
copi
number
remain
determin
mention
introduct
factor
often
impact
neg
laboratori
decis
use
molecular
diagnost
one
cost
worth
consid
matter
assay
chosen
use
attract
overhead
need
provid
infrastructur
laboratori
setup
ie
build
util
staff
equip
regard
cheap
test
use
reagent
cost
sole
factor
determin
assay
use
somewhat
pervers
reagent
cost
strip
higher
commerci
immunofluoresc
reagent
factor
includ
extract
would
undoubtedli
narrow
immunofluoresc
capabl
close
pathogen
gap
current
exist
eg
hrv
hmpv
current
use
approach
abl
replac
immunofluoresc
viral
cultur
abil
make
molecular
diagnost
cost
effect
method
diagnos
viral
infect
take
account
superior
rang
sensit
abil
quantifi
speed
molecular
techniqu
incred
littl
use
routin
laboratori
advent
sar
threat
avian
influenza
deficit
begin
disturb
health
care
planner
highest
level
specimen
sampl
contigu
season
peak
detect
account
small
number
respiratori
syncyti
viru
detect
lack
detect
human
metapneumovirus
parainfluenza
viru
type
coronaviru
subsequ
unpublish
data
routin
use
molecular
strip
support
import
role
human
metapneumoviru
acut
respiratori
infect
sporad
natur
infect
caus
parainfluenza
type
coronaviru
sever
interest
observ
need
highlight
first
immunofluoresc
perform
reliabl
essenti
good
nasopharyng
specimen
avail
use
throat
andor
nasal
swab
immunofluoresc
alon
inappropri
second
immunofluoresc
poor
detect
virus
patient
commun
almost
certainli
univers
use
swab
set
third
rapid
result
immunofluoresc
complement
touchdown
protocol
report
definit
result
within
hour
consider
faster
cultur
fourth
molecular
strip
better
detect
multipl
infect
even
allow
inabl
immunofluoresc
detect
rhinovirus
detect
mix
adenoviru
influenza
viru
infect
although
immunofluoresc
capabl
diagnos
dual
infect
routin
use
along
cultur
probabl
grossli
underestim
preval
plausibl
explan
molecular
techniqu
detect
infect
one
virus
posit
control
detect
threshold
immunofluoresc
low
level
virus
either
start
like
reach
end
infecti
episod
latenc
less
like
rais
previous
unaddress
question
role
viral
respiratori
pathogenesi
fifth
extent
rhinoviru
infect
signific
clinic
signific
rang
act
definit
respiratori
pathogen
less
certain
role
act
frequent
detect
copathogen
mix
infect
conclus
use
touchdown
protocol
predispens
qualiti
check
primer
mastermix
suitabl
replac
viru
cultur
diagnosi
respiratori
virus
immunofluoresc
neg
specimen
immunofluoresc
result
avail
averag
hour
molecular
strip
result
avail
within
hour
consider
faster
viral
cultur
combin
strip
touchdown
protocol
conveni
reliabl
method
test
multipl
virus
routin
set
gener
natur
make
especi
use
introduc
test
repertoir
modif
eg
incorpor
primer
newli
identifi
coronavirus
sarscov
total
specimen
includ
valid
januari
june
includ
influenza
surveil
scheme
specimen
collect
patient
includ
male
median
age
femal
patient
median
age
male
femal
age
skew
toward
lower
age
rang
nation
extern
qualiti
assur
scheme
neqa
specimen
posit
neg
one
hundr
fiftynin
patient
hospit
commun
time
sampl
specimen
test
consist
wide
rang
specimen
includ
bronchoalveolar
lavag
nasopharyng
secret
sputum
combin
throat
nasal
swab
nasopharyng
secret
bronchoalveolar
lavag
sputum
specimen
receiv
dri
steril
contain
ambient
temperatur
upon
receipt
resuspend
ml
viru
transport
medium
vtm
consist
phosphat
buffer
salin
ph
bovin
serum
albumin
penicillin
g
sodium
unitsml
streptomycin
sulphat
amphotericin
b
throat
nasal
swab
receiv
ml
vtm
vortex
arriv
releas
cell
attach
fibr
swab
aliquot
taken
extract
specimen
centrifug
g
min
result
cell
deposit
airdri
glass
multiwel
slide
fix
aceton
prior
test
immunofluoresc
set
respiratori
specimen
use
commerci
reagent
accord
manufactur
instruct
abl
detect
influenza
influenza
b
respiratori
syncyti
viru
adenoviru
parainfluenza
type
parainfluenza
type
parainfluenza
type
dako
diagnost
eli
uk
protocol
allow
coextract
rna
dna
simultan
simultan
amplif
target
facilit
use
standard
well
multiwel
pcr
strip
mix
predispens
store
frozen
format
refer
paper
respiratori
strip
respiratori
natur
target
respiratori
strip
target
follow
common
respiratori
virus
influenza
influenza
influenza
b
respiratori
syncyti
viru
type
respiratori
syncyti
viru
type
b
adenoviru
coronaviru
parainfluenza
viru
type
parainfluenza
viru
type
parainfluenza
viru
type
human
rhinoviru
human
metapneumoviru
final
configur
singl
multiplex
primer
mix
well
strip
shown
tabl
primer
set
use
taken
mainli
publish
studi
also
includ
primer
set
valid
inhous
modif
denovo
design
includ
influenza
influenza
gener
adenoviru
primer
primer
gene
target
expect
product
size
follow
amplif
shown
tabl
primer
mastermix
madeup
titrat
known
posit
control
aliquot
dispens
respect
well
microtub
strip
strip
store
frozen
use
posit
control
also
aliquot
store
separ
use
durat
studi
posit
control
clone
target
parainfluenza
viru
type
neg
control
deem
necessari
first
round
volum
madeup
access
rtpcr
buffer
promega
southampton
england
uk
final
volum
contain
follow
reagent
amount
agc
aaa
gct
ttc
agc
aac
tg
haemagglutinin
fla
gct
tcc
att
tgg
agt
gat
fla
agt
gct
gaa
cgt
gac
tat
gc
fla
ttt
gct
ggc
ttc
tct
tgg
rsv
gtc
tta
cag
ccg
tga
tta
gg
nucleoprotein
rsv
ggg
ctt
tct
ttg
gtt
act
tc
rsva
gat
gtt
acg
gtg
ggg
agt
ct
rsva
gta
cac
tgt
agt
taa
tca
ca
rsvb
aat
gct
aag
atg
ggg
agttc
rsvb
gaa
att
gag
tta
atg
aca
gc
adv
gccgcagtggtcttacatgcacatc
hexon
adv
cagcacgccgcggatgtcaaagt
adv
gacgcctcggagtacctswsycc
adv
tacgagtacgtggtgtcctckcgrtc
first
round
reaction
ad
second
round
primer
mastermix
per
well
multichannel
pipett
facilit
transfer
volum
one
step
posit
control
run
eighth
well
strip
second
round
product
run
ethidium
bromid
stain
agaros
gel
photograph
specimen
report
posit
respect
correct
size
band
posit
control
band
present
